舒洛地特治疗慢性静脉疾病患者血清特性的变化及其对内皮细胞修复的影响
研究纳入10例C2s期慢性静脉疾病(CVD)患者,比较功能不全大隐静脉与体循环血清炎症标志物,并观察舒洛地特(2×500脂解单位/日)治疗2个月前后对人脐静脉内皮细胞功能的影响。结果显示功能不全静脉血清VCAM-1较体循环升高29%(P<.001),内皮细胞MMP-9合成增加17%(P<.01)并出现衰老标志;舒洛地特治疗后内皮炎症标志物及基因表达降低。
要点
- 功能不全大隐静脉血清VCAM-1较体循环升高29%(P<.001),提示局部炎症更重。
- CVD血清使内皮细胞MMP-9合成增加17%(P<.01)并促进衰老标志表达。
- 舒洛地特治疗2个月后内皮炎症标志物及相应基因表达较治疗前降低。
核心结论
- CVD患者小腿功能不全大隐静脉与体循环的循环炎症标志物存在显著差异,提示CVD存在更高的炎症状态。
- 舒洛地特治疗降低CVD患者血清的促炎及内皮细胞活化特性。
研究设计与样本
- 研究纳入10例CVD(C2s)患者,于舒洛地特(2×500脂解单位/日)治疗2个月前后的功能不全大隐静脉和体循环静脉取血检测炎症标志物。
- 将治疗前后静脉血血清用于体外培养的人脐静脉内皮细胞功能评估。
主要发现
- 小腿功能不全大隐静脉血清VCAM-1较体循环血清升高29%(P<.001)。
- 未治疗CVD患者功能不全小腿静脉血清使内皮细胞MMP-9合成增加17%(P<.01),并增加衰老标志(群体倍增时间延长、β-半乳糖苷酶活性及p21、p53基因表达)。
- CVD血清诱导的衰老内皮细胞IL-6、MMP-9、VCAM-1和vWF合成基因表达升高。
- 功能不全大隐静脉血清对内皮细胞的总体促炎作用强于体循环血清。
- 舒洛地特治疗后静脉血清引起的内皮细胞炎症标志物及相应基因表达低于研究开始时(治疗前)的血清,且舒洛地特降低衰老内皮细胞的炎症分泌活性。
临床怎么用
- 作者指出,糖胺总糖(舒洛地特)治疗可成功控制和下调炎症标志物表达、内皮功能障碍及内皮细胞衰老转化。
- 作者认为需进一步研究确认糖胺总糖应用能否通过调节及下调潜在CVD相关病理过程来预防CVD临床进展。
局限性
- 原文指出需进一步研究确认糖胺总糖应用能否预防CVD临床进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Inflammation and endothelial dysfunction are important venous changes in patients with chronic venous disease (CVD). The use of the venoactive drugs remains an important treatment modality for patients with CVD, reducing the severity of the CVD-related symptoms and swelling but also reducing inflammation and protecting endothelial cells. In this research, the effects of the serum obtained from patients with CVD before and after sulodexide treatment were evaluated for in vivo and in vitro inflammatory markers and endothelial cell function. METHODS: Inflammatory markers (IL-6, matrix metalloproteinase-9 [MMP-9], vascular cell adhesion molecule-1 [VCAM-1], and von Willebrand factor [vWF]) from the incompetent great saphenous veins (GSVs) and from the systemic venous circulation were studied in 10 patients with CVD (C2s) before and after 2 months of sulodexide (2 × 500 lipasemic units/d) therapy. Serum obtained from the vein blood before and after sulodexide treatment was evaluated for in vitro cultured human umbilical vein endothelial cell function. RESULTS: The serum collected from lower leg incompetent GSVs had significantly elevated levels of VCAM-1 (+29%, P < .001) compared with the serum from the systemic circulation. Endothelial cells exposed to the serum from the incompetent lower leg veins of the untreated CVD patients demonstrated higher stimulated synthesis of MMP-9 (+17%, P < .01), as well as increased markers of senescence (prolongation of population doubling time, β-galactosidase activity, and expression of p21 and p53 genes). CVD serum-induced senescent endothelial cells had a higher expression of genes regulating IL-6, MMP-9, VCAM-1, and vWF synthesis. The overall proinflammatory effect on endothelial cells by the serum collected from the incompetent GSVs was stronger as compared with the serum from the systemic circulation. Serum collected from the veins after sulodexide treatment caused lower levels of endothelial cell inflammatory markers as well as respective gene expression than serum obtained at the beginning of the study (before sulodexide treatment). Sulodexide application also reduced the inflammatory secretory activity of the senescent endothelial cells. Sulodexide treatment resulted in the decrease of the majority of the studied inflammatory parameters in both lower limb incompetent vein and systemic blood. CONCLUSIONS: In patients with CVD, there are significant differences between circulating inflammatory markers analyzed from the lower leg incompetent GSV segments compared with the systemic circulation, indicating a higher inflammatory condition in CVD. Treatment with sulodexide reduces the proinflammatory and endothelial cell activation properties of the serum from patients with CVD. CLINICAL RELEVANCE: The study documented the significant proinflammatory human vascular endothelial cell activation when exposed to the serum collected from the varicose veins as compared with the serum from the systemic circulation in patients with chronic venous disease (CVD). The inflammatory marker expression, endothelial dysfunction, and endothelial cell senescence transformation can be successfully controlled and downregulated by patients' exposure to the glycosaminoglycan (sulodexide) treatment. Further studies are needed to confirm if glycosaminoglycan application can prevent further CVD clinical progression due to potential CVD-related pathological processes' modulation and their downregulation.
引用
- Zieliński A, Jasińska-Sumińska K, Bręborowicz A, et al. Changes of the serum properties and its effect on the endothelial cells restoration in patients with chronic venous disease treated with sulodexide. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 38945361. doi:10.1016/j.jvsv.2024.101941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。